Display Settings:

Format

Send to:

Choose Destination

    Science. 1996 Jul 12;273(5272):239-42.

    Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.

    Choi J, Chen J, Schreiber SL, Clardy J.

    Department of Chemistry, Baker Laboratory, Cornell University, Ithaca, NY 14853-1301, USA.

    Comment in:

    Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-associated protein (FRAP). A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resolution of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously. The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins. The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects observed for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasia mutant gene product, and it illustrates how a small cell-permeable molecule can mediate protein dimerization.

    PMID: 8662507 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Structures reported by this article

    Patient drug information

    • Tacrolimus (Prograf®)

      Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received kidney, liver, or heart transplants. ...

    • Sirolimus (Rapamune®)

      Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of medications called immunosuppressants. It works by suppressing the body's immune system.